BCL2 and small cell lung carcinoma: Furthermore, the oncofetal protein ROR1 was coexpressed with BCL-2 in multiple tumors, including SCLC, and functional experiments revealed that the ROR1 inhibitor (KAN0441571C) in combination with venetoclax produced synergistic effects in SCLC models [145].